Daniel Alpert, MD
Gastroenterology · New York, NYNPI 1063412708
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,093 of the $10,134 with a category attached, or 70.0%. 27 manufacturers reported payments, led by Olympus America Inc. at 29.3% of the total. Reporting peaked in 2024 at $4,482 and has fallen 74.0% since, to $1,165 in 2025.
Across 357 payments — averaging $28.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus America Inc.$3K
- QOL Medical, LLC$2K
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$810
- Johnson & Johnson$499
- Pfizer$498
- plus $3K from 21 others
Across 8 payments — averaging $2773.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ironwood Pharmaceuticals, Inc$22K
What the payments were for
- Food & beverage$7,09370%
- Education$721%
- Other$2,97029%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus America Inc. | 1 | $2,970 |
| QOL Medical, LLC | 77 | $1,736 |
| AbbVie(2 entities) | 64 | $1,068 |
| Takeda Pharmaceuticals U.S.A., Inc. | 44 | $810 |
| Johnson & Johnson | 19 | $499 |
| Pfizer | 27 | $498 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 22 | $404 |
| Regeneron Healthcare Solutions, Inc. | 13 | $341 |
| Bristol Myers Squibb | 18 | $291 |
| Phathom Pharmaceuticals, Inc. | 11 | $248 |
| Merck | 14 | $217 |
| Madrigal Pharmaceuticals | 7 | $195 |
| Sanofi | 6 | $177 |
| Redhill Biopharma Inc. | 9 | $156 |
| Braintree Laboratories, Inc. | 4 | $90 |
| Ardelyx, Inc. | 4 | $88 |
| Lilly USA, LLC | 3 | $78 |
| Amgen | 2 | $49 |
| Ferring Pharmaceuticals Inc. | 2 | $48 |
| Ironwood Pharmaceuticals, Inc | 2 | $39 |
| Gilead | 2 | $38 |
| Shield Therapeutics Inc | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Seqirus USA Inc | 1 | $16 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Intercept Pharmaceuticals, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,134 in reported general payments places this provider in the 80th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SucraidSacrosidase | 18 | $248,779 |
| CreonLipase/Protease/Amylase | 14 | $55,805 |
| LinzessLinaclotide | 71 | $41,905 |
| Dexlansoprazole DrDexlansoprazole | 75 | $21,345 |
| Mesalamine | 44 | $18,640 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 98 | $16,711 |
| EliquisApixaban | 16 | $13,851 |
| OzempicSemaglutide | 14 | $12,858 |
| MotegrityPrucalopride Succinate | 12 | $9,919 |
| VoqueznaVonoprazan Fumarate | 11 | $9,256 |
| Pantoprazole Sodium | 762 | $7,351 |
| Spiriva RespimatTiotropium Bromide | 12 | $5,658 |
| Lubiprostone | 26 | $3,498 |
| Famotidine | 292 | $2,976 |
| Budesonide DrBudesonide | 18 | $1,469 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| QOL Medical, LLCSucraid | $1,736 | $248,77918 claims |
| AbbVieCreon, Linzess | $1,068 | $97,70985 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $48 | $16,71198 claims |
| PfizerEliquis | $498 | $13,85116 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $810 | $9,91912 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $248 | $9,25611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,682 gastroenterology providers in New York.
Other gastroenterology in New York
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
- Bruce SandsNew York$810K
- Jean Frederick ColombelNew York$786K
- Seth GrossNew York$624K
- Caterina Oneto ArayaNew York$610K
- Dana LukinNew York$491K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.